Faraday Pharmaceuticals, Inc.

Our Faraday team members had a productive day 1 at #ASHP24. Please visit us at booth #1928 to learn how Faraday is targeting ischemia-reperfusion injury to reduce cardiac damage and heart failure.

Our team is looking forward to joining ASHP at #ASHP24 in New Orleans! Find us in Booth 1928 to learn how Faraday is targeting ischemia-reperfusion injury to reduce cardiac damage and heart failure. #FDY_5301 #IocyteAMI3

Faraday Pharmaceuticals to Participate in Jefferies London Healthcare Conference. See the full press release https://lnkd.in/gyxBM_Wi #faradaypharma #IocyteAMI3 #FDY_5301 #JefferiesHealthcare

Our Faraday team members had a productive day 1 at #TCT24. Please visit us at booth #1029 to learn how Faraday is targeting ischemia-reperfusion injury to reduce cardiac damage and heart failure. Don’t forget to pick up a notebook and pen to jot down your thoughts!

We're heading to #washingtondc this weekend for the Transcatheter Cardiovascular Therapeutics (TCT) annual symposium #TCT24 organized by the Cardiovascular Research Foundation (CRF). This event is a fantastic opportunity to engage with investigators and colleagues involved in our ongoing Phase 3 clinical trial, #IocyteAMI3, cultivate new connections, and explore the latest innovations.  

With the #ESCCongress starting this weekend, we are looking forward to reconnecting with colleagues, presenting exciting science in our satellite symposium, and forming new relationships.

We will be hosting a satellite symposium during ESC Congress 2024 featuring Dr. Roxana Mehran (Icahn School of Medicine at Mount Sinai), Dr Matt Cavender, MD, MPH (University of North Carolina Hospitals – Chapel Hill), and Dr. Keith Channon (University of Oxford). Untapped and forgotten: controversies in the treatment of ischaemia-reperfusion injury.  https://lnkd.in/gK-5Kexr

We are excited to be participating in #ESCCongress in #London. Please visit booth G220 or attend our satellite symposium - Untapped and forgotten: controversies in the treatment of ischaemia-reperfusion injury (IRI) – to learn more about how Faraday is targeting IRI to reduce cardiac damage and heart failure. https://lnkd.in/gK-5Kexr

In case you missed our KOL Webinar, you can view it on demand here: https://lnkd.in/gFRxaePk

Join Faraday Pharmaceuticals, Inc. for a KOL webinar on Tues. July 30 at 11am ET with Dr. Cheerag Shirodaria (Oxford University Hospitals), Dr. Marc Bonaca (University of Colorado Anschutz), and Dr. Antonio Gutierrez (Duke University Hospital and Durham VA Medical Center), who will discuss the unmet need and current treatment landscape in preventing ischemia-reperfusion injury and highlight the effects of STEMI on heart failure and other patient outcomes. Register here: https://bit.ly/4eXHjro